Supplement 1. Study protocol

```
┌─────────────────────────────────────────────────────────────┐
│              Assessment of eligibility                        │
│                                                               │
│  Included patients with EGJ and esophageal cancer since       │
│              Jan 2011–Jun 2019                                │
│                                                               │
│                    (n=332)                                    │
└─────────────────────────────────────────────────────────────┘
```

Exclusion

- Metastasis at presentation and initial palliative aim (n=93)
- Surgery upfront (n=18)
- Insufficient data or loss to follow-up (n=18)
- Induction chemotherapy (n=20)
- Definitive radiation (n=10)

```
┌─────────────────────────────────────────────┐
│        Preoperative/Definitive CRT           │
│                                              │
│                 (n=170)                      │
│                                              │
│        Assessment of body weight at          │
│        diagnosis                             │
│                                              │
│             (Body weight 1)                  │
└─────────────────────────────────────────────┘
```

```
┌──────────────────────┐        ┌──────────────────────┐
│       Preop CRT       │        │     Definitive CRT    │
│                       │        │                       │
│        (n=78)         │        │        (n=92)         │
└──────────────────────┘        └──────────────────────┘
```

```
                                ┌──────────────────────────┐
                                │  Excluded incomplete CRT  │
                                │                           │
                                │          (n=3)            │
                                └──────────────────────────┘
```

```
┌──────────────────────────────┐   ┌──────────────────────────────┐
│ Assessment Body weight post CRT│  │ Assessment Body weight post CRT│
│                                │  │                                │
│       (Body weight 2)          │  │       (Body weight 2)          │
└──────────────────────────────┘   └──────────────────────────────┘
```

```
┌──────────────────────────────┐   ┌──────────────────────────────┐
│         Data analysis          │  │         Data analysis          │
│                                │  │                                │
│            (n=78)              │  │            (n=89)              │
└──────────────────────────────┘   └──────────────────────────────┘
```

**Supplement 2.** Univariate and multivariate analyses of odds ratios for predicting weight loss during CRT treatment in overall patients

Variable	Univariate			Multivariate		
	OR	95% CI	P value	OR	95% CI	P value
AGE (years) <65 **vs** ≥65	0.68	0.36 - 1.28	0.24	-	-	-
Sex Male **vs** Female	0.53	0.20-1.44	0.218	-	-	-
Stage T1-2 **vs** T3-4 N0 **vs** N+	1.83 0.70	0.86-3.89 0.32-1.52	0.115 0.372	- 	- 	-
Pretreatment laboratory values - Albumin > 3.0 vs ≤3.0 g/dL - Hb ≥ 10 vs <10 g/dL	0.96 0.66	0.39-2.33 0.89-1.77	0.931 0.513	- 	- 	-
Esophageal site upper **vs** - **Middle** - **Lower** - **EGJ**	1.49 1.86 4.26	0.71 – 3.10 0.77-4.47 0.411-44.1	0.283 0.163 0.224	- - -	- - -	- - -
Aim of Radiation Preop **vs** definitive	0.69	0.38-1.28	0.243	-	-	-
Feeding route - Oral **vs** feeding tube	1.35	0.975-1.87	0.07	-	-	-
Complications before treatment - No **vs** Yes	3.25	1.00-10.52	0.049	2.98	0.90-9.84	0.072
Concomitant chemotherapy regimen - Carboplatin/paclitaxel **vs** Cisplatin/5FU	2.18	1.16 – 4.07	0.015	2.07	1.09-3.94	0.026

Supplement 3. Surgical outcomes of patients undergoing preoperative CRT

Surgical outcome	LWL (n=35)	HWL(n=43)	P value
Surgery			
Yes	21(60%)	17(39.5%)	0.072
No	14(40%)	26(60.5%)	
Mean duration from start of CRT to surgery (days) + SD	94.7 + 26.01	142.8+181	0.235
Postoperative mortality after 90 days	4(19.05%)	1(5.88%)	0.233
Pathological complete response (%)	11(57.8%)	5(31.2%)	0.115